Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,~* have ≥6 swollen joints (from a 66 joint count) and ≥8 tender joints (from a 68 joint count) at Screening and at Baseline,~* Screening serum c-reactive protein ≥0.7 x upper limit of laboratory normal range (ULN),~* have received MTX for ≥6 months and have been on a stable dose (15 to 25 mg/week) of MTX for at least 4 weeks prior to Screening and willing to continue on their current regimen for the duration of the study. Stable doses of MTX as low as 10 mg/week are allowed when there is documented evidence of intolerance or safety issues at higher doses.~Exclusion Criteria:~* current therapy with any disease-modifying anti-rheumatic drugs (DMARD) other than MTX,~* current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs administered in a single clinical study setting more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,~* previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent \[%\] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.
- GLPG0634 50 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
- GLPG0634 100 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
- GLPG0634 200 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
- GLPG0634 25 mg BID (Type: EXPERIMENTAL): Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.
- GLPG0634 50 mg BID (Type: EXPERIMENTAL): Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.
- GLPG0634 100 mg BID (Type: EXPERIMENTAL): Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete